In 18 patients with Schistosoma haematobium infection the urinary blood loss was measured by labelling the red blood cells in vivo with 59Fe. 9 of the 18 had recurrent severe haematuria with bright to dark red urine; the other 9 had occasional terminal haematuria and clear urine. In those with severe haematuria the daily blood loss ranged from 2·6 to 126 ml., and the daily iron loss from 0·6 to 37·3 mg. There was no calculated blood loss in the patients with occasional terminal haematuria and clear urine.

Ten Egyptian male farmers, aged 9-43 years, with Schistosoma hœmatobium infection and urological complications were treated with tartar emetic or sodium dimercaptosuccinate (' Astiban ', Roche). The results were assessed clinically, radiologically, and functionally 2-3 months after the end of the course of treatment. Seven of the ten patients aged 9-23 years showed clear clinical, radiological, and functional improvement. Treatment of the older patients was less successful.

Comparative antimony disposition was investigated after the administration of three antimonial drugs to patients infected with Schistosoma haematobium; the drugs were sodium antimony dimercaptosuccinate (Astiban®), antimony dimercaptosuccinic acid (Astiban Acid in Oil®), and tartar emetic. Samples investigated were plasma, red blood cells, urine, and S. haematobium eggs excreted with the urine.